Nifty
:
18124.50
Sensex
:
60838.03
-53.60 (-0.29%)
-85.47 (-0.14%)
Nifty
Sensex
:
:
18124.50
60838.03
-53.60 (-0.29%)
-85.47 (-0.14%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
40/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
502.75
21-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  507.75
  •  513.45
  •  495.50
  •  505.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1156583
  •  5812.26
  •  690.95
  •  442.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,183.18
  • 13.87
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,731.45
  • 0.50%
  • 1.93

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 1.07%
  • 16.02%
  • FII
  • DII
  • Others
  • 25.93%
  • 8.56%
  • 1.77%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.53
  • 3.81
  • 3.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.30
  • 0.46
  • 5.62

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.74
  • -2.64
  • 1.60

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.44
  • 16.20
  • 15.25

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.59
  • 2.95
  • 2.23

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.39
  • 10.38
  • 9.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
2,964.89
2,344.79
26.45%
2,859.90
2,767.49
3.34%
2,786.76
2,735.56
1.87%
2,952.48
2,815.04
4.88%
Expenses
2,391.32
1,866.72
28.10%
2,336.47
2,301.80
1.51%
2,256.69
2,295.49
-1.69%
2,399.67
2,364.63
1.48%
EBITDA
573.58
478.07
19.98%
523.43
465.69
12.40%
530.07
440.08
20.45%
552.81
450.41
22.73%
EBIDTM
19.35%
20.39%
18.30%
16.83%
19.02%
16.09%
18.72%
16.00%
Other Income
58.65
58.51
0.24%
8.49
44.14
-80.77%
15.09
32.96
-54.22%
-31.88
80.83
-
Interest
75.60
93.74
-19.35%
83.33
98.47
-15.38%
95.41
96.06
-0.68%
80.63
89.77
-10.18%
Depreciation
113.07
113.22
-0.13%
111.07
126.28
-12.04%
115.20
106.00
8.68%
104.07
94.16
10.52%
PBT
443.55
357.61
24.03%
337.51
317.96
6.15%
347.97
270.98
28.41%
339.38
347.30
-2.28%
Tax
137.03
103.57
32.31%
103.65
97.65
6.14%
99.79
80.14
24.52%
105.38
91.76
14.84%
PAT
306.53
254.04
20.66%
233.87
220.31
6.15%
248.18
190.84
30.05%
233.99
255.54
-8.43%
PATM
10.34%
10.83%
8.18%
7.96%
8.91%
6.98%
7.93%
9.08%
EPS
10.86
9.00
20.67%
8.29
7.81
6.15%
8.80
6.76
30.18%
8.29
9.06
-8.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
11,564.03
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
Net Sales Growth
8.45%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
 
Cost Of Goods Sold
4,029.42
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
Gross Profit
7,534.61
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
GP Margin
65.16%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
Total Expenditure
9,384.15
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
Power & Fuel Cost
-
164.67
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
% Of Sales
-
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
Employee Cost
-
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
% Of Sales
-
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
Manufacturing Exp.
-
804.63
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
% Of Sales
-
7.35%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
General & Admin Exp.
-
825.28
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
678.94
1,331.99
% Of Sales
-
7.54%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
Selling & Distn. Exp.
-
979.64
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
% Of Sales
-
8.95%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
Miscellaneous Exp.
-
121.44
47.19
33.29
314.55
88.52
38.82
38.48
228.40
33.61
0.00
% Of Sales
-
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
EBITDA
2,179.89
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
EBITDA Margin
18.85%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
Other Income
50.35
50.22
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
Interest
334.97
353.11
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
Depreciation
443.41
443.55
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
PBT
1,468.41
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
Tax
445.85
412.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
Tax Rate
30.36%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
PAT
1,022.57
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
PAT before Minority Interest
1,022.57
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
Minority Interest
0.00
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
PAT Margin
8.84%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
PAT Growth
11.06%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
 
EPS
36.24
34.37
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97
16.31

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
Total Reserves
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
Non-Current Liabilities
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
Unsecured Loans
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
Current Liabilities
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
Trade Payables
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
Other Current Liabilities
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
Short Term Borrowings
513.01
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
Short Term Provisions
564.45
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
Total Liabilities
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
Net Block
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
Gross Block
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
Accumulated Depreciation
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
Non Current Assets
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
Capital Work in Progress
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
Non Current Investment
24.63
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
Long Term Loans & Adv.
146.29
123.97
94.36
119.78
98.94
69.99
468.16
33.39
36.52
0.00
Other Non Current Assets
27.89
26.49
15.80
0.56
0.13
0.16
0.27
20.33
22.00
33.23
Current Assets
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
Sundry Debtors
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
Cash & Bank
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
Other Current Assets
1,371.53
603.30
765.22
810.78
1,273.61
986.77
774.38
872.81
635.91
593.95
Short Term Loans & Adv.
672.06
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
Net Current Assets
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
Total Assets
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
PBT
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
Adjustment
644.82
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
Changes in Working Capital
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
Cash after chg. in Working capital
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
Net Fixed Assets
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
Net Investments
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
Others
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
Cash from Financing Activity
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
Net Cash Inflow / Outflow
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
Opening Cash & Equivalents
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
Closing Cash & Equivalent
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
249.60
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
ROA
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
ROE
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
ROCE
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
Fixed Asset Turnover
1.29
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
Receivable days
83.06
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
Inventory Days
73.58
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
Payable days
93.71
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
Cash Conversion Cycle
62.94
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
Total Debt/Equity
0.67
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
Interest Cover
4.92
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Glenmark Pharmaceuticals launches Tavulus for COPD treatment in Spain
    11th Oct 2021, 10:36 AM

    Tavulus is expected to provide relief to a large patient population in the country

    Read More
  • Glenmark receives marketing approval for Ryaltris in 13 countries across EU and UK
    30th Sep 2021, 09:19 AM

    Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age

    Read More
  • Glenmark Pharma concludes study on COVID drug Favipiravir
    15th Sep 2021, 17:20 PM

    The study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients

    Read More
  • Glenmark Pharmaceuticals reports 21% rise in Q1 consolidated net profit
    14th Aug 2021, 10:44 AM

    Total consolidated income of the company marginally increased by 25.81% at Rs 3023.54 crore for Q1FY22

    Read More
  • Glenmark Pharmaceuticals inks pact with Canadian biotech SaNOtize
    2nd Aug 2021, 10:43 AM

    The partnership aims to manufacture, market and distribute its breakthrough NONS for COVID-19 treatment in India and other Asian markets

    Read More
  • Glenmark Pharmaceuticals’ arm to invest Rs 600 crore to double capacity in four years
    23rd Jul 2021, 09:20 AM

    The capacity expansion is on the back of company's plan to enter more regulated growth markets

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.